{
    "Trade/Device Name(s)": [
        "Pointe Scientific Creatine Kinase (CK) Reagent Set"
    ],
    "Submitter Information": "MedTest Dx",
    "510(k) Number": "K191296",
    "Predicate Device Reference 510(k) Number(s)": [
        "K043202"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGS"
    ],
    "Summary Letter Date": "July 8, 2020",
    "Summary Letter Received Date": "July 10, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatine Kinase"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum separator tube (SST)",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Shenzhen Mindray BA-800M Chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay",
        "NADP/NADPH absorbance measurement",
        "Kinetic procedure (Szasz-Rosalki modification)"
    ],
    "Methodologies": [
        "Quantitative enzymatic activity determination"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Pointe Scientific Creatine Kinase (CK) Reagent Set for quantitative determination of creatine kinase activity in serum and plasma",
    "Indications for Use Summary": "Quantitative determination of creatine kinase activity in serum and plasma to aid diagnosis and treatment of myocardial infarction and muscle disease, including progressive Duchenne-type muscular dystrophy",
    "fda_folder": "Clinical Chemistry"
}